Glaukos Corp. Earnings Call Signals High-Growth Phase

Glaukos Corp. ((GKOS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Glaukos Corp.’s latest earnings call struck a distinctly upbeat tone as management celebrated record quarterly and full‑year revenue while highlighting rapid uptake of its flagship glaucoma implant, iDose TR, and the FDA approval of Epioxa. Executives acknowledged near‑term launch frictions and higher spending, but framed these as manageable execution issues against a backdrop of strong demand and a robust innovation pipeline.

Record Revenue Caps a Breakout Year

Glaukos reported record Q4 2025 consolidated net sales of $143.1 million, up 36% on a reported basis and 34% in constant currency versus the prior year. Full‑year 2025 net sales also hit a record at $507.4 million, representing 32% growth over 2024 and underscoring the company’s accelerating commercial momentum across glaucoma and corneal health.

2026 Outlook: Reaffirmed Guidance and Strong Growth

The company reaffirmed its 2026 net sales outlook of $600 million to $620 million, implying more than 20% year‑over‑year growth at the midpoint and roughly $100 million of incremental revenue versus 2025. Management emphasized that this guidance already factors in product launch costs, transition volatility in corneal health, and international competition, indicating confidence in underlying demand.

iDose TR Fuels U.S. Glaucoma Expansion

U.S. glaucoma net sales surged to $86.4 million in Q4, up 53% from a year ago, driven largely by iDose TR, which contributed about $45 million in the quarter and roughly $136 million for 2025. For 2026, management expects U.S. glaucoma revenue to grow about 30% year over year, with iDose TR providing all of that growth as adoption broadens and sequential gains continue each quarter.

Epioxa Approval Marks a New Corneal Chapter

The FDA approved Epioxa in Q4 as the first topical, incision‑free corneal cross‑linking therapy for keratoconus, eliminating the need for epithelial removal. Glaukos has begun commercial launch activities and expects drug availability later in the current quarter, positioning Epioxa as a potentially transformative option for patients and a new pillar of the corneal franchise.

Building Epioxa’s U.S. Site Network and Access

Glaukos is rapidly rolling out its O2n systems, reporting deployments in locations that already cover nearly 50% of the U.S. population and a pipeline expected to bring coverage closer to 90%. On the payer front, the company has engaged insurers representing about half of commercially covered lives, including four of the five largest commercial payers, laying the groundwork for broader reimbursement.

Early Coding Wins Support Epioxa Adoption

Management highlighted several early positive coverage determinations for Epioxa from both commercial plans and Medicaid, an important step for real‑world uptake. While a permanent J‑code has been submitted and is expected to become effective in July 2026, the product will initially be reimbursed through a new technology miscellaneous J‑code, which may slow early momentum but still enables access.

International and Corneal Franchise Still Growing

International glaucoma revenue reached $32.8 million in Q4, up 18% reported and 13% in constant currency, reflecting healthy overseas demand despite rising competition. Corneal health net sales were $24.0 million in the quarter, up 12% year over year and driven by $21.4 million from Photrexa, with management projecting only modest growth in 2026 as the franchise transitions to Epioxa.

Pipeline Investments Underpin Long‑Term Story

Glaukos stressed its commitment to innovation, noting it has invested over $1 billion in R&D since inception and continues to fund a broad pipeline. Among recent milestones, the company completed iStent infinite PMA enrollment, advanced the PRESERFLO pivotal 510(k) trial, initiated Phase IIb/III work for iDose TREX, kicked off a Phase IIIb iDose TRIO study, and progressed both its iLink KC screening tool and retinal program GLK‑401.

Balancing Growth with Capital Discipline

The CFO outlined a strategy to balance aggressive growth investments with disciplined spending, targeting cash‑flow breakeven or better in 2026. Operating expenses are expected to rise in the mid‑teens percent year over year as Glaukos funds the Epioxa rollout and other launches, but management still anticipates operating leverage as revenue scales.

Parsing iDose’s Q4 Sequential Slowdown

Management acknowledged a sequential deceleration signal in iDose TR during Q4, though the product still delivered sequential growth “north of 10%.” The slowdown was attributed largely to a shift in payer mix toward Medicare Advantage and incentive timing that pulled some volume into Q3, and the company does not see this as a structural demand issue.

Epioxa Faces Early Coding and Payer Friction

Executives cautioned that initial Epioxa uptake will be constrained by the pace of site‑of‑care deployments and payer adoption, especially while the product is billed under a miscellaneous J‑code. These coding and prior‑authorization frictions are expected to elongate approval timelines in the near term, resulting in more measured early adoption despite strong clinical positioning.

Managing the Photrexa to Epioxa Transition

The shift from Photrexa to Epioxa is expected to create notable timing volatility in corneal health revenue during 2026, particularly around the second quarter. Management forecast modest year‑over‑year growth in Q1, a potentially material dip in Q2 as patients enter the approval pipeline, a flattish Q3 as the permanent J‑code comes online, and a stronger exit in Q4 as the transition stabilizes.

International Competition Adds Headwinds

Abroad, Glaukos expects new competitive product trialing to weigh on growth in several major markets through 2026, offsetting some benefits from iStent infinite. As a result, the company is guiding to high single‑digit international glaucoma growth for the full year, even though certain quarters could see stronger performance depending on competitive dynamics.

Re‑Administration Potential and Product Mix Uncertainty

The FDA label now allows unlimited re‑administration of iDose TR in patients with healthy corneas, a change that could add a meaningful recurring component to the franchise over time. However, management indicated that re‑administration is not a major factor in the 2026 outlook and acknowledged uncertainty about future cannibalization between iDose TR and the longer‑acting TREX version once both are commercial.

Higher OpEx to Support Launches Weighs on Margins

Operating expenses are expected to land in the mid‑hundreds of millions of dollars and grow in the mid‑teens percentage range year over year as Glaukos invests behind Epioxa and its broader portfolio. While this will pressure margins in the near term, the company believes these outlays are necessary to scale its new platforms and ultimately drive higher profitability.

Regulatory and Coverage Risks Still on the Radar

Management flagged the possibility of local coverage determinations from Medicare Administrative Contractors that could affect access to iDose TR, even though they view such moves as premature and not likely today. Nonetheless, they acknowledged this as an ongoing risk factor investors should monitor, given the product’s central role in the growth story.

Guidance and Growth Drivers for 2026

Looking ahead, Glaukos reaffirmed 2026 net sales guidance of $600 million to $620 million, implying more than 20% growth from the $507.4 million posted in 2025 and reflecting confidence in sequential gains for iDose TR throughout the year. The outlook also assumes high single‑digit international glaucoma growth, modest but choppy corneal expansion through the Photrexa‑to‑Epioxa transition, mid‑teens operating expense increases, expanding Epioxa coverage and site deployment, and the incremental benefit of label changes such as iDose TR’s unlimited re‑administration.

Glaukos’ earnings call painted the picture of a company in the midst of a major growth phase, powered by record revenue and strong adoption of innovative eye‑care technologies. While launch‑related friction, higher spending, and regulatory uncertainties pose near‑term challenges, management’s reaffirmed guidance and deep pipeline suggest a long runway for expansion that will attract close attention from growth‑oriented investors.